Yoshiki Hata

Hachioji, JP 
Hachioji, JP 

Overview

Yoshiki Hata practices practicing medicine in Hachioji, Japan.

His clinical expertise encompasses Coronary Heart Disease, Acute Coronary Syndrome, Xanthoma, Heart Attack, and Percutaneous Coronary Intervention (PCI).

He is actively involved in clinical research, co-authoring 36 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Hachioji, Japan
Other Locations
Minamino, Japan
Minamino, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Drug
Study Drugs: Dulaglutide, Biguanide (BG), Sulfonylurea (SU), Alpha-Glucosidase Inhibitors (?-GI), Thiazolidinedione (TZD), Glinides (GLN), Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i)
Study Phase: Phase 3

36 Total Publications

Esaxerenone versus angiotensin II receptor blockers as second-line therapy in older Japanese patients with uncontrolled hypertension on calcium channel blockers: the randomized, open-label ESCORT-HT study.
Esaxerenone versus angiotensin II receptor blockers as second-line therapy in older Japanese patients with uncontrolled hypertension on calcium channel blockers: the randomized, open-label ESCORT-HT study.
Journal: Hypertension research : official journal of the Japanese Society of Hypertension
Published: February 06, 2026

Frequently Asked Questions about Yoshiki Hata

Is Yoshiki Hata a top-rated expert for Percutaneous Coronary Intervention (PCI)?

MediFind is an objective health platform that identifies experts based on real-world data. Yoshiki Hata is classified as an Experienced expert for Percutaneous Coronary Intervention (PCI), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yoshiki Hata participate in research or clinical trials?

Yes. Yoshiki Hata has published 36 articles and abstracts on conditions like Percutaneous Coronary Intervention (PCI). You can view a list of Yoshiki Hata's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hata's expertise for a condition
ConditionClose
        View All 11 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile